Beta Bionics, Inc. (BBNX) Reports Q4 Loss, Tops Revenue Estimates

Core Viewpoint - Beta Bionics, Inc. reported a quarterly loss of $0.3 per share, which is better than the Zacks Consensus Estimate of a loss of $0.42, showing an earnings surprise of +28.57% [1] Financial Performance - The company posted revenues of $32.12 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.07% and showing a year-over-year increase from $20.44 million [2] - Over the last four quarters, Beta Bionics has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Beta Bionics shares have declined approximately 54.3% since the beginning of the year, contrasting with the S&P 500's slight decline of 0.1% [3] - The current Zacks Rank for Beta Bionics is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.51 on revenues of $28.39 million, and for the current fiscal year, it is -$1.89 on revenues of $131.82 million [7] - The trend of estimate revisions for Beta Bionics was unfavorable prior to the earnings release, which may impact future stock movements [6] Industry Context - The Medical - Instruments industry, to which Beta Bionics belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]